FDA Compliance for Peptide Therapy and BPC 157 Holt Law Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement Stevens & Lee In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for RFK Jr. promotes peptides. Now the FDA weighs easing limits on the unproven chemicals Musculoskeletal and Tissue Healing with BPC 157: Weight Loss and Vitality: Medical Weight Loss